Recombinant Human 4-1BB/TNFRSF9 Fc Chimera Protein, CF

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

4-1BB, also known as CD137 and TNFRSF9, is an approximately 30 kDa transmembrane glycoprotein in the TNF receptor superfamily. 4-1BB functions in the development and activation of multiple immune cells (1). Mature human 4-1BB consists of a 163 amino acid (aa) extracellular domain (ECD) with four TNFR cysteine‑rich repeats, a 27 aa transmembrane segment, and a 42 aa cytoplasmic domain (2, 3). Within the ECD, human 4-1BB shares 60% aa sequence identity with mouse and rat 4-1BB. 4-1BB is expressed as a disulfide-linked homodimer on various populations of activated T cell including CD4⁺, CD8⁺, memory CD8⁺, NKT, and regulatory T cells (4-7) as well as on myeloid and mast cell progenitors, dendritic cells, mast cells, and bacterially infected osteoblasts (8-11). It binds with high affinity to the transmembrane 4-1BB Ligand/TNFSF9 which is expressed on antigen presenting cells and myeloid progenitor cells (3, 8). This interaction co‑stimulates the proliferation, activation, and/or survival of the 4-1BB expressing cell (3-7). It can also enhance the activation-induced cell death of repetitively stimulated T cells (3). Mice lacking 4-1BB show augmented T cell activation, perhaps due to its absence on regulatory T cells (12). 4-1BB can associate with OX40 on activated T cells, forming a complex that responds to either ligand and inhibits Treg and CD8⁺ T cell proliferation (13). Reverse signaling through 4-1BB Ligand inhibits the development of dendritic cells, B cells, and osteoclasts (8, 11) but supports mature dendritic cell survival and co‑stimulates the proliferation and activation of mast cells (9, 10).
4‑1BB activation enhances CD8⁺ T cell and NK cell mediated anti-tumor immunity (14). It also contributes to the development of inflammation in high fat diet-induced metabolic syndrome (15). Soluble forms of 4-1BB and 4-1BB Ligand circulate at elevated levels in the serum of rheumatoid arthritis and hematologic cancer patients, respectively (16, 17).

We have publications tested in 1 confirmed species: Human.

We have publications tested in 1 application: Bioassay.

Showing Publications 1 - 5 of 5.

Publications using 838-4B	Applications	Species
K Weigand, G Peschel, J Grimm, K Luu, D Schacherer, R Wiest, M Müller, H Schwarz, C Buechler Soluble CD137 is a novel serum marker of liver cirrhosis in patients with hepatitis C and alcohol-associated disease etiology European Journal of Immunology, 2021-12-26;0(0):. 2021-12-26 [PMID: 34914098] (Bioassay, Human)	Bioassay	Human
Transcriptional and functional characterization of CD137L-dendritic cells identifies a novel dendritic cell phenotype Sci Rep, 2016-07-19;6(0):29712. 2016-07-19 [PMID: 27431276] (Bioassay, Human)	Bioassay	Human
Harfuddin Z, Kwajah S, Chong Nyi Sim A, Macary P, Schwarz H CD137L-stimulated dendritic cells are more potent than conventional dendritic cells at eliciting cytotoxic T-cell responses. Oncoimmunology, 2013-11-11;2(11):e26859. 2013-11-11 [PMID: 24482752] (Bioassay, Human)	Bioassay	Human
Moh M, Lorenzini P, Gullo C, Schwarz H Tumor necrosis factor receptor 1 associates with CD137 ligand and mediates its reverse signaling. FASEB J, 2013-04-25;27(8):2957-66. 2013-04-25 [PMID: 23620528] (Bioassay, Human)	Bioassay	Human
Maniar A, Zhang X, Lin W, Gastman BR, Pauza CD, Strome SE, Chapoval AI Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement. Blood, 2010-06-02;116(10):1726-33. 2010-06-02 [PMID: 20519625] (Bioassay, Human)	Bioassay	Human

Array 838-4B

• 4-1BB/TNFRSF9/CD137 Antibodies
• 4-1BB/TNFRSF9/CD137 ELISA Kit
• 4-1BB/TNFRSF9/CD137 Proteins
• 4-1BB/TNFRSF9/CD137 ELISAs
• 4-1BB/TNFRSF9/CD137 Proteins and Enzymes